Giuseppe Lo Russo - JoVE Visualize

Showing results (121-130 of 137) with videos related to

Pageof 14

Sort By:

Therapeutic Advances in Medical Oncology|October 22, 2019

Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.

JTO Clinical and Research Reports|February 16, 2023

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.

Lancet (London, England)|November 6, 2023

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023

STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.

Frontiers in Oncology|February 9, 2023

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patientsArsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, et al.

Medrxiv : the Preprint Server for Health Sciences|November 24, 2025

Combining Clinician Expertise with Prompt Engineering enhances Small Language Models Reliability for Cancer Entity Recognition in Electronic Health RecordsFederica Corso, Vittoria Peppoloni, Laura Mazzeo, et al.

The Oncologist|December 24, 2025

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.

Cancer|May 30, 2026

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.

Journal of the National Cancer Institute|April 12, 2023

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort studyLuca Cantini, Francesco Paoloni, Federica Pecci, et al.

Gastroenterology|April 16, 2018

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin AnaloguesSara Pusceddu, Claudio Vernieri, Massimo Di Maio, et al.

Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:

Pageof 14

Therapeutic Advances in Medical Oncology|October 22, 2019

Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.

JTO Clinical and Research Reports|February 16, 2023

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.

Lancet (London, England)|November 6, 2023

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023

STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.

Frontiers in Oncology|February 9, 2023

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patientsArsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, et al.

Medrxiv : the Preprint Server for Health Sciences|November 24, 2025

Combining Clinician Expertise with Prompt Engineering enhances Small Language Models Reliability for Cancer Entity Recognition in Electronic Health RecordsFederica Corso, Vittoria Peppoloni, Laura Mazzeo, et al.

The Oncologist|December 24, 2025

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.

Cancer|May 30, 2026

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.

Journal of the National Cancer Institute|April 12, 2023

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort studyLuca Cantini, Francesco Paoloni, Federica Pecci, et al.

Gastroenterology|April 16, 2018

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin AnaloguesSara Pusceddu, Claudio Vernieri, Massimo Di Maio, et al.

Pageof 14